Developing precision BioGene therapeutics designed to overcome treatment resistance and improve outcomes for patients with difficult-to-treat cancers
EPIGENOMAX THERAPEUTICS LLC
Transforming Cancer Treatment by Addressing One of Oncology's Greatest Challenges
EpigenoMax Therapeutics is advancing a new generation of precision oncology solutions that combine molecular diagnostics with targeted BioGene therapeutics to identify, attack and eliminate cancer with greater precision.
EpigenoMax Therapeutics LLC
Solving One of Oncology's Biggest Unmet Needs
Cancer treatment has advanced dramatically over the past decade, yet many patients ultimately develop treatment resistance that limits long-term therapeutic success.
EpigenoMax is developing precision BioGene therapeutics designed to overcome these barriers through highly targeted biological interventions that selectively eliminate cancer cells while minimizing effects on healthy tissue.
Precision Diagnostics That Guide Better Treatment Decisions
Our molecular diagnostic technologies are designed to detect cancers at the molecular level, providing the insights needed to personalize therapy and improve treatment selection.
Earlier, more precise diagnosis enables more informed clinical decision-making and supports our integrated therapeutic strategy.
Precision-Targeted BioGene Therapeutics
Our proprietary therapeutic platform is designed to deliver programmable, highly specific BioGene therapies that target malignant cells while reducing unnecessary exposure to healthy tissue.
This approach has the potential to improve therapeutic efficacy and expand treatment options for patients facing difficult-to-treat cancers.
An Integrated Precision Oncology Platform
Rather than viewing diagnosis and treatment as separate steps, EpigenoMax is developing an integrated platform that connects molecular diagnostics with precision-targeted therapeutics.
This unified approach seeks to improve clinical decision-making, personalize therapy and enhance treatment outcomes across the patient journey.
Patient-Centered Care
Everything we do begins with patients.
Our mission is to develop innovative precision oncology solutions that help physicians deliver more effective treatments while giving patients facing cancer new reasons for hope.
Scientific innovation is meaningful only when it improves lives.
Building the Future of Precision Oncology
Why EpigenoMax?
Addressing a Significant Clinical Need
Treatment resistance remains one of the leading causes of cancer treatment failure.
Integrated Precision Platform
Combining molecular diagnostics with programmable BioGene therapeutics.
Differentiated Technology
Designed to improve treatment specificity while advancing personalized oncology.
Experienced Scientific Leadership
Built upon years of oncology research focused on translating scientific discovery into clinical impact.
Committed to Improving Patient Outcomes
Developing innovative therapies with the potential to transform cancer care.
Get in touch
Telephone: +12039078908
E-mail: xianyong.ma@epigenomax.com
Address: 101 College St, New Haven, 06510-2407, Connecticut, United States